Tagged with generics

biosimilars Akhilesh Vijay came to Accord Healthcare Peru following a career at Intas Pharmaceutical in India. He urges the implementation of regulation for Biosimilars and discusses his strategy for future growth as a leading Indian generic affiliate. How did you integrate yourself here, and what was the initial strategy? What is…

generics The president of both Polymédic, a local producer, and AMMG, the Moroccan generics association, discusses the role of generics in the Moroccan market today, and what steps the country must take in order to realize its pharma potential. Morocco pioneered the pharmaceutical industry in Africa; yet, today investors are fewer…

distribution The CEO of ZenithPharma discusses the potential of Africa for Moroccan pharma companies, and what it takes to succeed in the Moroccan pharma market. ZenithPharma’s headquarters are located in Agadir. Why did you choose Agadir? Historically, we started our business in the pharmaceutical industry here when we opened a wholesale…

association The CEO of Morocco’s oldest pharma association discusses the latest regulatory changes in Morocco and their impact on its members, as well as the position of Moroccan pharma in the African and European context. You have significant experience in the pharmaceutical industry in Morocco. What have been the key steps…

access The general manager of Iberma discusses the history of the Moroccan pharmaceutical industry, new measures to improve access, and working on Moroccan-European partnerships in the pharma sector. You have a long experience of the Moroccan pharmaceutical industry. What have been the most significant changes throughout its history? Morocco initiated its…

association The president of Turkey’s oldest pharmaceutical industry association discusses the government’s reluctance to reform the pricing system, and how this is causing the absorption of the domestic Turkish pharmaceutical industry by global big pharma. Turkey has traditionally been a branded generic market; how are these players performing at present? Roughly…

Zentiva The GM of one of the leading generics companies on the Romanian market shares insights into why generics penetration remains underdeveloped and the importance of having an export strategy and diversified portfolio.   You have been in your current position since 2009, witnessing many changes. Can you introduce Zentiva in…

generics After Brazil, Torrent is looking to strengthen its foothold in the Mexican market. The general manager of the local affiliate explains the opportunities Latin America offers to Indian companies, how – despite an apparent slackening performance – the Mexican pharmaceutical market is growing and how niche is the name of…

generics At Valeant each region has a unique mix of prescription brands, branded generics and OTC products. The general manager for Mexico, Central America, the Caribbean and the Andean region discusses the company’s objectives for Spanish speaking Latin America and how it plans to leverage the recently acquired Bausch+Lomb business to…

biosimilars Brothers Juan José and Andrés Aguirre Salazar of Grupo Bruluart talk about the company’s most important milestones and how they are institutionalizing the family business to prepare the firm for new market opportunities. Could you walk us through the most important milestones of the company and provide our readers with…

generics Carlos Leigh, executive president of Peru’s Asociación de Laboratorios Farmacéuticos Latinoamericanos (ALAFAL), discusses the advantages that LATAM companies have over big pharma players looking to enter the Peruvian market, and offers his predictions for the future of the sector for growth. Can you introduce yourself to our readers? I actively worked in…

R&D Brian Wang, CEO of Korean super-generics developer GL PharmTech, discusses Korea’s relative strengths in different stages of R&D, and how this motivated the foundation and evolution of GL PharmTech. What was the inspiration that prompted you to found GL PharmTech, a company based on incrementally modified drugs, back in 2002?…